FDA approves first pill to treat all forms of hepatitis C

The Food and Drug Administration approved the combination pill, Epclusa, from Gilead Sciences for patients with and without liver damage. Gilead's previous two hepatitis drugs have raked in billions of dollars by replacing an older, less effective treatment that involved a grueling pill-and-injection cocktail. But the company's aggressive approach to pricing has drawn scorn from patient groups, insurers and politicians worldwide.